These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2873245)

  • 41. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
    Giaffer MH; O'Brien CJ; Holdsworth CD
    Aliment Pharmacol Ther; 1992 Feb; 6(1):51-9. PubMed ID: 1347468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of sulphasalazine on neutrophil superoxide generation in rheumatoid arthritis.
    Bradley SM; le Gallez P; Throughton PR; Gooi HC; Astbury C; Bird HA
    Br J Rheumatol; 1997 May; 36(5):530-4. PubMed ID: 9189053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma and synovial fluid concentrations of sulphasalazine and two of its metabolites in rheumatoid arthritis.
    Farr M; Brodrick A; Bacon PA
    Rheumatol Int; 1985; 5(6):247-51. PubMed ID: 2906452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimation of 5-aminosalicylic acid and its metabolite in human serum by front-face fluorometry: a simple and sensitive method.
    Hirsch RE; Lin MJ; Das KM
    J Lab Clin Med; 1990 Jul; 116(1):45-50. PubMed ID: 2376696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Active therapeutic moiety of sulphasalazine.
    van Hees PA; van Tongeren JH; Bakker JH; van Lier HJ
    Lancet; 1978 Feb; 1(8058):277. PubMed ID: 74700
    [No Abstract]   [Full Text] [Related]  

  • 46. Biochemical and clinical changes occurring during the treatment of rheumatoid arthritis with novel antirheumatoid drugs.
    Dixon JS; Bird HA; Martin MF; McKenna F; Wright V
    Int J Clin Pharmacol Res; 1985; 5(1):25-33. PubMed ID: 2860075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of salazosulfapyridine and its metabolites on immunocompetent cells].
    Ishibashi T; Hara A; Tsuboi I; Muraoka T; Shibata H; Tsunosue R; Shichijo S; Yokoyama M
    Ryumachi; 1989 Jun; 29(3):178-84. PubMed ID: 2573159
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo.
    Sheldon P; Pell P
    Adv Exp Med Biol; 1995; 371B():905-8. PubMed ID: 7502923
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
    Astbury C; Taggart AJ; Juby L; Zebouni L; Bird HA
    Ann Rheum Dis; 1990 Aug; 49(8):587-90. PubMed ID: 1975737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid.
    Ambrosius Christensen L; Rasmussen SN; Hansen SH; Bondesen S; Hvidberg EF
    Acta Obstet Gynecol Scand; 1987; 66(5):433-5. PubMed ID: 2892343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
    van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
    Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sulphasalazine in the treatment of rheumatoid arthritis.
    Box SA; Pullar T
    Br J Rheumatol; 1997 Mar; 36(3):382-6. PubMed ID: 9133974
    [No Abstract]   [Full Text] [Related]  

  • 54. Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis.
    Akiyama Y; Sakurai Y; Kato Y; Furuta E; Mimura T
    Mod Rheumatol; 2014 Mar; 24(2):285-90. PubMed ID: 24252022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Which component of sulphasalazine is active in rheumatoid arthritis?
    Situnayake RD; McConkey B
    Br Med J (Clin Res Ed); 1985 Jul; 291(6488):138. PubMed ID: 2861878
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis.
    Roediger W; Schapel G; Lawson M; Radcliffe B; Nance S
    Biochem Pharmacol; 1986 Jan; 35(2):221-5. PubMed ID: 2867767
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
    Taggart AJ; McDermott B; Delargy M; Elborn S; Forbes J; Roberts SD; Ahnfelt NO
    Scand J Rheumatol Suppl; 1987; 64():29-36. PubMed ID: 2893450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of sulphasalazine and its metabolites on prostaglandin production by human mononuclear cells.
    Punchard NA; Boswell DJ; Greenfield SM; Thompson RP
    Biochem Pharmacol; 1992 Jun; 43(11):2369-76. PubMed ID: 1351726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-trimoxazole in rheumatoid arthritis: a comparison with sulphapyridine.
    Astbury C; Hill J; Bird HA
    Ann Rheum Dis; 1988 Apr; 47(4):323-7. PubMed ID: 3284488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis.
    Pirmohamed M; Coleman MD; Galvani D; Bucknall RC; Breckenridge AM; Park BK
    Br J Rheumatol; 1993 Mar; 32(3):222-6. PubMed ID: 8095423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.